Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Dermata Therapeutics Inc. Warrant (DRMAW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: DRMAW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.57 | 52 Weeks Range 0.01 - 0.03 | Updated Date 06/14/2025 |
52 Weeks Range 0.01 - 0.03 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -95.9% | Return on Equity (TTM) -206.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 4154323 |
Shares Outstanding - | Shares Floating 4154323 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Dermata Therapeutics Inc. Warrant
Company Overview
History and Background
Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focused on identifying, developing, and commercializing innovative, first-in-class, and differentiated dermatology products. Founded with a mission to address unmet needs in dermatology, the company aims to improve the lives of patients with skin diseases.
Core Business Areas
- Medical Dermatology: Focuses on developing treatments for common skin conditions such as acne, rosacea, and psoriasis. Their clinical development pipeline targets these diseases with novel drug candidates.
Leadership and Structure
Dermata Therapeutics is led by a team of experienced executives in the biotechnology and pharmaceutical industries. The organizational structure typically includes departments for research and development, clinical operations, regulatory affairs, and commercial strategy.
Top Products and Market Share
Key Offerings
- DM-199 (Sebustat): DM-199 is being developed for the treatment of acne and rosacea. Currently in clinical development. Market share is not yet available, but potential competitors include established acne and rosacea treatments from companies like Galderma (Rosacea) and various generics for acne.
- DM-200 (combination product): DM-200 is being developed for the treatment of acne and rosacea. Currently in clinical development. Market share is not yet available, but potential competitors include established acne and rosacea treatments from companies like Galderma (Rosacea) and various generics for acne.
Market Dynamics
Industry Overview
The dermatology market is characterized by increasing demand for effective treatments for skin diseases, driven by factors such as aging populations, rising awareness of skin health, and advancements in dermatology research.
Positioning
Dermata Therapeutics aims to differentiate itself through the development of innovative and first-in-class treatments for common skin conditions, providing potential therapeutic advantages over existing options.
Total Addressable Market (TAM)
The global dermatology market is expected to reach hundreds of billions of dollars. Dermata Therapeutics is positioned to capture a share of this market with its novel therapies, targeting significant unmet needs.
Upturn SWOT Analysis
Strengths
- Novel Drug Candidates
- Experienced Management Team
- Focus on Unmet Needs in Dermatology
- Proprietary Technologies
Weaknesses
- Early Stage Clinical Development
- Limited Financial Resources
- Dependence on Clinical Trial Outcomes
- Lack of Commercialized Products
Opportunities
- Partnerships with Larger Pharmaceutical Companies
- Successful Clinical Trial Results
- Expansion into New Dermatology Indications
- Market Growth in Dermatology Treatments
Threats
- Competition from Established Dermatology Companies
- Clinical Trial Failures
- Regulatory Hurdles
- Generic Competition
Competitors and Market Share
Key Competitors
- GILD
- SNY
- BAYRY
Competitive Landscape
Dermata Therapeutics faces competition from established dermatology companies with commercialized products and larger R&D budgets. They aim to differentiate through innovative therapies addressing unmet needs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily measured by progress in clinical trials and expansion of the drug development pipeline.
Future Projections: Future growth is dependent on successful clinical trial outcomes and potential commercialization of their drug candidates.
Recent Initiatives: Recent initiatives would include advancing clinical trials for their lead drug candidates and exploring potential partnerships.
Summary
Dermata Therapeutics is a clinical-stage biotechnology company with innovative dermatology products in development. The company is exposed to clinical trial risk and requires funding to progress its pipeline. Successful trials and strategic partnerships are key to the company's future success. Its success hinges on successful clinical trials and the subsequent commercialization of its novel therapies to treat a variety of unmet needs in the dermatology market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be based on thorough research and consultation with a financial advisor. Market share estimations are approximations based on available data and may not be precise. Financial data and projections are forward-looking statements and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dermata Therapeutics Inc. Warrant
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-08-13 | Founder, President, CEO & Chairman Mr. Gerald T. Proehl | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.dermatarx.com |
Full time employees 8 | Website https://www.dermatarx.com | ||
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.